Medicinal products me too: value in the pharmaceutical market
https://doi.org/10.22328/2077-9828-2022-14-2-91-97
Abstract
Introduction. According to expert estimates, most of medicinal products, presented in the pharmaceutical market, are metoo. However, there is no established definition of the term.
The objective of research is to assess the value of medicinal products metoo for the modern society.
Materials and Methods. Systematic observation and analysis of publications, related to medicinal products metoo.
Results and discussion. It was found that despite the spread of medicinal products metoo, this term is not defined in the legal sphere of any country which means there is no judicial system to control the appearance of innovative products in the market, raising doubt about the objectivity of financing, costs refund of medical technologies. Meanwhile, there are possible advantages among the medicinal products metoo, both comparing each other and regarding premium ones in their category.
Conclusion. On the one hand, metoo is considered to be low-innovative medicinal products. However, there can be more effective and safer medicinal products among them, comparing already existing ones in the pharmaceutical market. On the other hand, such a wide spread leads to some obstacles for really innovative products, premium in their category. Therefore, metoo is a pressing issue for the world scientific community.
About the Authors
V. G. Borovskaya
Pavlov First St. Petersburg State Medical University
Russian Federation
Russian Federation
St. Petersburg
A. A. Kurilyov
Pavlov First St. Petersburg State Medical University; The National Medical Research Centre of Oncology after N. N. Petrov
Russian Federation
Russian Federation
St. Petersburg
A. S. Kolbin
Pavlov First St. Petersburg State Medical University; The St. Petersburg State University
Russian Federation
Russian Federation
Alexey S. Kolbin
St. Petersburg
References
1. Aronson J.K., Green A.R. Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists // Br. J. Clin. Pharmacol. 2020. Vol. 86, No. 11. Р. 2114–2122. doi: 10.1111/bcp.14327.
2. Régnier S. What is the value of ‘me-too’ drugs? // Health Care Manag. Sci. 2013. Vol. 16, No. 4. Р. 300–313. doi: 10.1007/s10729-013-9225-3.
3. Востокова Н.В., Трахтенберг Ю.А., Смолярчук Е.А., Свистунов А.А. Возможности применения адаптивного дизайна в клинических исследованиях препаратов // Ведомости научного центра экспертизы средств медицинского применения. 2016. № 4. С. 36–41 [Vostokova N.V., Trakhtenberg Yu.A, Smolyarchuk E.A., Svistunov A.A. Possibilities of adaptive design implementation in clinical trials of nextin-class drugs. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 2016, No. 4, рр. 36–41 (In Russ.)].
4. Омельяновский В.В., Сура М.В., Свешникова Н.Д. Новые лекарственные препараты. Как оценить инновационность? // Педиатрическая фармакология. 2011. Т. 8, № 4. C. 30–35 [Omelyanovsky V.V., Sura M.V., Sveshnikovf N.D. Pediatric Pharmacology, Vol. 8, No. 8, рр. 30– 35 (In Russ.)].
5. Айтян Т. В. Причины и последствия высоких цен на лекарственные препараты в США. Пути решения // Ars Administrandi (Искусство управления). 2018. Т. 10, № 1. С. 168–180. [Aytyan T.V. Origins and Consequences of High Prices on Drugs in the USA. Ways of Solution. Ars Administrandi, 2018, Vol. 10, No. 1, pp. 168–180. doi: 10.17072/2218-9173-2018-1-168-180 (In Russ.)].
6. Корзинов О.В., Балакин К.В., Иващенко А.А. Фармацевтический скрининг в России: прямой или обратный? // Ремедиум. 2007 [Pharmaceutical screening in Russia: direct or reverse? Remedium. 2007. P. 12–17 (In Russ.)].
7. Cohen J., Kaitin K. Follow-on drugs and indications: The importance of incremental innovation to medical practice // Am. J. Ther. 2008. Vol. 15, No. 1. Р. 89–89. doi: 10.1097/MJT.0b013e31815f9e52.
8. Lee T.H. Me-Too Products — Friend or Foe ? // The New England Journal of Medicine. 2004. January 15 P. 211–212.
9. Huskamp H.A. Prices, profits, and innovation: Examining criticisms of new psychotropic drugs’ value // Health Aff. 2006. Vol. 25, No. 3. Р. 635– 646. doi: 10.1377/hlthaff.25.3.635.
10. Azoulay P. Do pharmaceutical sales respond to scientific evidence? // J. Econ. Manag. Strateg. 2002. Vol. 11, No. 4, рp. 551–594, doi: 10.1162/105864002320757262.
11. Мусина Н.З., Федяева В.К., Омельяновский В.В., Хачатрян Г.Р., Герасимова К.В., Лемешко В.А., Кончиц К.П. Обзор существующих зарубежных подходов к определению и оценке инновационности лекарственных препаратов // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2017. Т. 10, № 3. С. 66–74. [Musina N.Z., Fedyaeva V.K., Omel’yanovskii V.V., Khachatryan G.R., Gerasimova K.V., Lemeshko V.A., Konchits K.P. Review of the current approaches to the assessment of the drug innovative potential worldwide. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology, 2017, Vol. 10, No. 3, рp. 66–74 (In Russ.)]. doi: 10.17749/2070-4909.2017.10.3.066-074.
12. Хачатрян Г.Р., Лунева А.В. Инновации в медицине и определение их ценности в зарубежных странах: обзор литературы // Международный опыт. 2013. № 4. С. 23–28 [Khachatryan G.R., Luneva A.V. Characteristics of Innovations in Medicine and Assessment of its Value: a Literature Review. International experience, 2013, No. 4, рр. 23–28 (In Russ.)].
Review
For citations:
Borovskaya V.G., Kurilyov A.A., Kolbin A.S. Medicinal products me too: value in the pharmaceutical market. HIV Infection and Immunosuppressive Disorders. 2022;14(2):91-97. (In Russ.) https://doi.org/10.22328/2077-9828-2022-14-2-91-97
Views:
783
.png)
Email this article 